Kharel Sanjeev, Shrestha Suraj, Shakya Prafulla, Rawat Rohit, Shilpakar Ramila
Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Department of Surgery, National Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal.
J Int Med Res. 2022 Mar;50(3):3000605221084874. doi: 10.1177/03000605221084874.
The mean platelet volume (MPV) is a measure of platelet size, and it is considered a surrogate marker of platelet activation. Because the correlation between platelet count/size and lung cancer prognosis remains unclear, this meta-analysis comprehensively evaluated the prognostic significance of MPV among patients with lung cancer.
A systematic search of PubMed, Embase, Google Scholar, and additional sources of relevant studies were conducted with no language restrictions from inception to 7 May 2021. Overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS), as well as their hazard ratios (HR) and 95% confidence intervals (CIs), were pooled to evaluate the relationship between MPV and survival. The study protocol was registered on PROSPERO.
Eleven studies involving 2421 patients with lung cancer were included in our analysis. Nine studies including only patients with non-small cell lung cancer were included in the meta-analysis. Our analysis revealed no significant associations of MPV with OS (HR = 1.09, 95% CI = 0.84-1.41) and DFS/PFS (HR = 1.13, 95% CI = 0.58-2.20).
Pretreatment MPV levels did not display prognostic significance in patients with NSCLC. Large-scale prospective studies and a validation study considering ethnicity and lung cancer staging are warranted.
平均血小板体积(MPV)是血小板大小的一种度量,并且它被认为是血小板活化的替代标志物。由于血小板计数/大小与肺癌预后之间的相关性仍不明确,本荟萃分析全面评估了MPV在肺癌患者中的预后意义。
对PubMed、Embase、谷歌学术以及其他相关研究来源进行了系统检索,检索范围从起始到2021年5月7日,无语言限制。汇总总生存期(OS)和无病生存期(DFS)/无进展生存期(PFS)及其风险比(HR)和95%置信区间(CI),以评估MPV与生存期之间的关系。该研究方案已在PROSPERO上注册。
我们的分析纳入了11项涉及2421例肺癌患者的研究。荟萃分析纳入了9项仅包括非小细胞肺癌患者的研究。我们的分析显示,MPV与OS(HR = 1.09,95%CI = 0.84 - 1.41)和DFS/PFS(HR = 1.13,95%CI = 0.58 - 2.20)均无显著相关性。
治疗前MPV水平在非小细胞肺癌患者中未显示出预后意义。有必要开展大规模前瞻性研究以及考虑种族和肺癌分期的验证研究。